# Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/HUMA/humacyte-announces-first-quarter-2026-financial-results-and-provides-business-update
Ticker: HUMA
Company: Humacyte
Source: Humacyte
Published: 2026-05-13 11:00 EST
Original Source URL: https://investors.humacyte.com
## Summary

- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and

## Article Body
- Appointed Jim Mercadante as Chief Commercial Officer and Dr. Todd Rasmussen as Chief Surgical Officer -  - First quarter sales of Symvess® were $0.5 million in 2026 compared to $0.1 million in 2025 - - Purchase commitment received for a minimum of $1.475 million for a clinical evaluation and
## Recent Company News
- 2026-05-26 12:00 EST — [Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access](https://biopharmsignal.com/news/HUMA/humacyte-announces-presentation-at-vasa-meeting-of-research-highlighting-self-repair-of-atev-after-cannulation-for-dialysis-access) — Source: Humacyte
- 2026-05-20 12:00 EST — [Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs](https://biopharmsignal.com/news/HUMA/humacyte-announces-symvessr-is-now-under-contract-with-the-strategic-acquisition-center-sac-of-the-u-s-department-of-veterans-affairs) — Source: Humacyte
- 2026-05-13 11:00 EST — [Humacyte Announces First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/HUMA/humacyte-announces-first-quarter-2026-financial-results-and-provides-business-update) — Source: Humacyte
- 2026-05-12 12:00 EST — [Humacyte Appoints Dr. Todd E. Rasmussen as Chief Surgical Officer](https://biopharmsignal.com/news/HUMA/humacyte-appoints-dr-todd-e-rasmussen-as-chief-surgical-officer) — Source: Humacyte
- 2026-05-08 12:00 EST — [Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026](https://biopharmsignal.com/news/HUMA/humacyte-to-announce-2026-first-quarter-financial-results-and-provide-business-update-on-may-13-2026) — Source: Humacyte
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)